Israel Saucedo, APRN
Acute Care · Tifton, GANPI 1003222191
Payments from drug & device makers
Across 84 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$494
- Novo Nordisk$472
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57
- Genentech USA, Inc.$55
- Pfizer$50
- Lilly USA, LLC$45
- plus $147 from 7 others
What the payments were for
- Food & beverage$1,321100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $494 |
| Novo Nordisk | 25 | $472 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $57 |
| Genentech USA, Inc. | 5 | $55 |
| Pfizer | 3 | $50 |
| Lilly USA, LLC | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Vertex | 1 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Medtronic | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| Merck | 1 | $13 |
How this compares
$1,321 in reported general payments places this provider in the 75th percentile of 679 acute care providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 11 | $1,369 |
| Cefdinir | 35 | $564 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $477 |
| Atorvastatin Calcium | 57 | $329 |
| Doxycycline Hyclate | 32 | $315 |
| Diclofenac Sodium | 14 | $257 |
| Ondansetron OdtOndansetron | 30 | $254 |
| Pantoprazole Sodium | 35 | $243 |
| Prednisone | 65 | $161 |
| Gabapentin | 14 | $161 |
| Tizanidine Hcl | 20 | $116 |
| Famotidine | 12 | $103 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $95 |
| Azithromycin | 19 | $94 |
| Dicyclomine Hcl | 12 | $91 |
Paid to pharmacies, not to this prescriber.
Other acute care in Tifton
- John DoddTifton$5K
- Zoye McDonaldTifton$3K
- Darryl TurnerRinggold$21K
- Bryce CowgillCumming$16K
- Stacy CreelSavannah$15K
- Susan BeitzellAthens$13K
- Crystal KuhnCumming$12K
- Mark ClarkGainesville$10K
- Sarah WymanAtlanta$10K
- Jeffrey DillerAustell$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.